T Cell Therapy Market is expected to reach US$ 9,035.01 million by 2030

Publisher: The Insight Partners

CAR T Cell Therapy Dominated Product Modality in T Cell Therapy Market

According to our new research study on "T Cell Therapy Market Forecast to 2030 – Global Analysis – by Modality, Therapy Type, and Indication," the T cell therapy market size was valued at US$ 2,754.0 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2022–2030.

T-cell transfer therapy is a type of immunotherapy that makes immune cells better able to attack cancer. There are two main types of T-cell transfer therapy: T cell therapy receptor (TCR) therapy and CAR T-cell therapy. Both are involved in collecting immune cells, grown in large numbers in the lab, and then intravenously delivered to the patient. T-cell transfer therapy is also called adoptive cell therapy, adoptive immunotherapy, and immune cell therapy.

The T cell therapy market, by modality, is bifurcated into research and commercialized. In 2022, the commercialized segment held a larger share of the market and is expected to grow at a faster rate during 2022–2030.

T-Cell Therapy Market

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00024331

The T cell therapy market, by therapy type, is segmented into CAR T-cell therapy and T-cell receptor (TCR)-based. In 2022, the CAR T-cell therapy segment held a larger share of the market and is expected to grow at a faster rate during 2022–2030. In the chimeric antigen receptor (CAR) T-cell therapy technique, T-cells obtained from patients are artificially bioengineered in such a way that they can express CARs that can identify and attach to the tumor cells. Strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T-cell segment fuel the T-cell therapy market growth for the segment. A few of the noteworthy developments in the CAR T-cell therapy are listed below:

• In July 2020, the FDA approved a CAR T-cell therapy brexucabtagene autoleucel (Tecartus) under the Accelerated Approval pathway. It is the first FDA-approved CAR T-cell therapy for mantle cell lymphoma. Tecartus also received Orphan Drug designation that encourages the development of drugs for rare diseases. Other approved CAR-T cell therapies for cancer are Kymriah for acute lymphoblastic leukemia and Yescarta for diffuse large B-cell lymphoma.
• In 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. It is an autologous CAR-T cell engineered with lentivirus to attack BCMA-expressing tumor cells to treat certain kinds of relapsed or refractory multiple myeloma. CARVYKTI is a kind of therapy called CAR-T—which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI is used to treat adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The T cell therapy market, by indication, is bifurcated into hematologic malignancies and solid tumors. In 2022, the hematologic malignancies segment held a larger share of the market and is estimated to register a significant CAGR during 2022–2030. Hematologic malignancies are cancer types that affect the blood, bone marrow, and lymph nodes of the human body. Leukemia, lymphoma, myeloid, and myeloma are a few types of hematologic malignancies. According to Leukemia and Lymphoma Society, in 2023, ~184,000 people in the US are expected to be diagnosed with leukemia, lymphoma, or myeloma. According to the same source, ~1.629,000 people in the US are affected by or in remission from hematologic malignancies. Due to an increase in the prevalence of hematologic malignancies across the world, treatment approaches have developed rapidly. CAR-T cell therapy has reformed the treatment of hematological malignancies in recent years, especially in relapsed/refractory (R/R) B-cell acute lymphocytic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). The US FDA approved seven CAR-T cell products such as CARVYKTI, YESCARTA, TECARTUS, BREYANZI, ABECMA, KYMRIAH, and FUCASO for hematologic malignancy treatment. In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI), manufactured by Janssen Biotech and Legend Biotech to treat relapsed or refractory multiple myeloma in adult patients.

Region Analysis – T Cell Therapy Market

Geographically, the T cell therapy market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The T-cell therapy market in North America is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players. Also, with an increase in clinical studies in CAR T-cell therapies, the market in North America is expected to grow during the forecast period. According to CDC, 1,603,844 new cancer cases were reported and 602,347 people died in the US in 2020. An estimated 184,720 people in the US will be diagnosed with leukemia, lymphoma, or myeloma in 2023.

Tisagenlecleucel (KymriahTM, Novartis, Morris Plains, NJ, US) and axicabtagene ciloleucel (YescartaTM, Gilead Sciences Canada, El Segundo, CA, US) were the first two CAR T-cells commercially available and approved in Canada by Health Canada in 2018 and 2019, respectively. Both are second-generation anti-CD19 CAR T-cells, approved for adult patients with r/r DLBCL, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. Moreover, Canadian-Led Immunotherapies in Cancer-01 (CLIC-01) is the first to introduce CAR T-cell therapy in Canada. It uses a different kind of cell manufacturing that unveils less expensive and more equitable treatment. The Queen Elizabeth II Health Sciences Centre in Halifax became the first facility in Atlantic Canada to offer CAR T-cell therapy locally as of March 2022. Prior to this, Nova Scotia patients who were recommended for this highly personalized cancer medicine had to travel outside the country to receive the treatment. The program was made possible with a government investment of US$ 6.7 million annually. Thus, the rising cancer cases and initiative by the government fuel the T-cell therapy market in North America.

Immunocore Holdings PLC, Legend Biotech Corp, Janssen Global Services LLC, Gilead Sciences Inc, Bristol Myers Squibb Co, Bluebird Bio Inc, Novartis AG, JW (Cayman) Therapeutics Co Ltd, Cartesian Therapeutics, and Innovent Biologics are among the leading companies operating in the T cell therapy market.

The report segments the T cell therapy market as follows:

The T cell therapy market is segmented into modality, therapy type, indication, and geography. By modality, the T cell therapy market is bifurcated into research and commercialized. Based on therapy type, the T cell therapy market is segmented into CAR T-cell therapy and T-cell receptor (TCR)-based. Based on indication, the T cell therapy market is segmented into hematologic malignancies and solid tumors. Geographically, the T cell therapy market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, Israel, and Rest of Middle East & Africa), and South & Central America (Brazil).

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com